Table 3.
Association between the use of sulfonylurea and the risk of any cancer in various subgroups of participants.
| Sulfonylureas | Metformin | HR (95% CI) | |||
|---|---|---|---|---|---|
| Cases/Person-years | Incidence (/100,000 person years) | Cases/Person-years | Incidence (/100,000 person years) | ||
| Age group | |||||
| <60 years | 138/24417 | 565 | 99/21088 | 469 | 1.14 (0.86–1.50) |
| ≥60 years | 324/30096 | 1077 | 192/18994 | 1011 | 1.08 (0.90–1.30) |
| Gender | |||||
| Female | 206/27397 | 752 | 122/19078 | 639 | 1.21 (0.95–1.54) |
| Male | 256/27117 | 944 | 169/21004 | 805 | 1.03 (0.84–1.26) |
| Drinking | |||||
| No | 301/35430 | 850 | 187/25764 | 726 | 1.08 (0.89–1.31) |
| Yes | 161/19084 | 844 | 104/14318 | 726 | 1.09 (0.84–1.42) |
| Smoking | |||||
| No | 270/37113 | 728 | 178/26828 | 663 | 1.01 (0.83–1.24) |
| Yes | 192/17401 | 1103 | 113/13254 | 853 | 1.23 (0.96–1.58) |
| FBG | |||||
| <7mmol/L | 221/23269 | 950 | 140/17380 | 803 | 1.14 (0.90–1.45) |
| ≥7mmol/L | 241/31244 | 771 | 151/22702 | 667 | 1.05 (0.83–1.33) |
| HBA1c | |||||
| <7% | 197/21862 | 900 | 125/16356 | 767 | 1.10 (0.74–1.63) |
| ≥7% | 265/32651 | 813 | 166/23727 | 698 | 1.08 (0.80–1.46) |
| Duration of T2DM | |||||
| <0.5 years | 210/25683 | 818 | 142/18547 | 766 | 0.99 (0.79–1.24) |
| ≥0.5 years | 252/28831 | 874 | 149/21535 | 692 | 1.17 (0.95–1.45) |
| CCI | |||||
| 0 | 346/44269 | 782 | 230/32842 | 700 | 1.03 (0.87–1.23) |
| ≥1 | 116/10244 | 1132 | 61/7240 | 843 | 1.34 (0.96–1.86) |